Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 689-697 , October 2010

Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines

  • Seyedeh Parinaz Akhlaghi, PharmD

      Affiliations

    • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Shahrooz Saremi, PharmD

      Affiliations

    • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Seyed Nasser Ostad, PhD

      Affiliations

    • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Rassoul Dinarvand, PhD

      Affiliations

    • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Medical nanotechnology Research Centre, Medical Sciences/University of Tehran, Tehran, Iran
    • ,
  • Fatemeh Atyabi, PhD

      Affiliations

    • Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    • Medical nanotechnology Research Centre, Medical Sciences/University of Tehran, Tehran, Iran
    • Corresponding Author InformationCorresponding author: Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, PO Box 14155-6451, Iran.

Received 14 September 2009 ,Accepted 25 January 2010.

References 

  1. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994;48:794–847
  2. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;333:75–81
  3. Schiff P, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature. 1979;277:665–667
  4. Koziaraa JM, Lockmanb PR, Allenb DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99:259–269
  5. Tarr BD, Yalkowsky SH. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs. Parenter Sci Technol. 1987;41:31–33
  6. Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133:11–17
  7. Singla K, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179–192
  8. Leroux JC, Doelker E, Gurny R. The use o obtained f drug-loaded nanoparticles in cancer chemotherapy. In:  Benita S editors. Microencapsulation. New York: Marcel Dekker; 1996;p. 535–575
  9. Thanou M, Verhoef J, Junginger H. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117–126
  10. Aghaei Moghaddam F, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine. 2009;5:208–215
  11. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004;58:327–341
  12. Bernkop-Schnurch A, Kast CE. Chemically modified chitosans as enzyme inhibitors. Adv Drug Deliv Rev. 2001;52:127–137
  13. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev. 2005;57:1569–1582
  14. Atyabi F, Talaie F, Dinarvand R. Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations. J Nanosci Nanotechnol. 2009;9:4593–4603
  15. Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release. 2003;93:95–103
  16. Atyabi F, Aghaie Moghaddam F, Dinarvand R, Zohuriaan-Mehr MJ, Ponchel G. Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization. Carbohydr Polym. 2008;74:59–67
  17. Chauvierre C, Labarre D, Couvreur P, Vauthier C. Radical polymerisation of alkylcyanoacrylates initiated by the redox system dextran–cerium (IV) under acidic aqueous conditions. Macromolecules. 2003;36:6018–6027
  18. Atyabi F, Majzoob S, Dorkoosh F, Sayyah M, Ponchel G. The impact of trimethyl chitosan on in vitro mucoadhesive properties of pectinate beads along different sections of gastrointestinal tract. Drug Dev Ind Pharm. 2007;33:291–300
  19. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166:68–75
  20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  21. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials. 2007;28:2233–2243
  22. Bravo-Osuna I, Schmitz T, Bernkop-Schnurch A, Vauthier CF, Ponchel G. Elaboration and characterization of thiolated chitosan-coated acrylic nanoparticles. Int J Pharm. 2006;316:170–175
  23. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21:344–356
  24. Kafedjiiski K, Foge F, Werle M, Bernkop-Schnurch A. Synthesis and in vitro evaluation of a novel chitosan–glutathione conjugate. Pharm Res. 2005;22:1480–1488
  25. Bilicic MB, Filipovic-Grcic J, Martinac A, Barbaric M, Zorc B, Cetina-Cizmek B, et al. Synthesis and characterization of thiomers of polyaspartamide type. Int J Pharm. 2005;291:211–219
  26. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly(lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials. 2009;30:3297–3306
  27. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polyeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–2722
  28. He M, Zhao Z, Yin L, Tang C, Yin C. Hyaluronic acid cotaed poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm. 2009;373:165–173
  29. Pauillard V, Nicolaou A, Double JA, Philips RM. Methionine dependence of tumours : a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. Biochem Pharmacol. 2006;71:772–778
  30. Bakogeorgoua E, Hatzogloub A, Castanasc E. Taxol inhibits opioid binding on T47D human breast cancer cells. Biochem Biophys Res Commun. 1997;235:201–204

PII: S1549-9634(10)00018-3

doi: 10.1016/j.nano.2010.01.011

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 689-697 , October 2010

Article Tools

* Image Usage & Resolution